The authors assessed the predictive capacity of 3 rule-based algorithms (Bergamo, Stanford University, Rega Institute) for HIV genotypic interpretation. A total of 1132 postgenotypic regimens in 533 patients were considered. The genotypic sensitivity score (GSS) was strongly associated (P < .0001) with the virologic outcome (1 log HIV-RNA reduction). The 3 algorithms had a highly significant prediction efficiency. The Bergamo algorithm receiver-operating characteristic curve area under the curve (AUC) for the prediction of ≥ ≥1 log HIV-RNA reduction was 0.753 (95% confidence interval, 0.725-0.781), testifying that the prediction was significantly different (P < .0001) from simple chance. The AUCs obtained by the 2 other systems were similar (0.752 Stanford; 0.741 Rega). The predictive capacity of the algorithms was not influenced by the type of antiviral drugs used. The 3 considered rule-based algorithms for the interpretation of HIV genotypic resistance yield congruent results and may effectively predict the virologic outcome of rescue therapy. Their use may help clinicians in interpreting mutational patterns and in making therapeutic choices.
HIV-1 drug resistance is one of the major factors limiting highly active antiretroviral therapy (HAART) efficacy. It has been shown that baseline genotypic or phenotypic drug resistance can alter the subsequent virologic response. [1] [2] [3] Moreover, HIV drug-resistance tests as a guide to HAART choice may improve the virologic outcome.
The most widely used resistance assays are genotypic tests based on nucleic acid sequencing of the viral reverse transcriptase and protease genes. These tests identify mutations associated with resistance to antiretroviral drugs. However, the rough list of mutations they provide needs some degree of interpretation by clinicians and virologists, as not all mutations are alike in terms of resistance. Furthermore, the interaction among different mutations can alter the effect of single substitutions, making the interpretation of genotypic assays even more complex. As a consequence, a large number of genotypic interpretation tools have been developed in recent years. [4] [5] [6] [7] They include mutation lists, rule-based algorithms, and databases correlating genotypes with the corresponding phenotype.
Several studies have reported that different expert systems show substantial disagreements in the interpretation of genotypic resistance, and their ability to predict virologic outcomes may substantially vary, too. [4] [5] [6] 8, 9 To assess their predictive capacity and to evaluate the grade of discordance of their prediction, we analyzed the performance of 3 rule-based algorithms on a large clinical cohort.
Materials and Methods

Study Patients and HAART Regimens
A retrospective analysis was conducted on patients referred to a single center in northern Italy. Patients were selected among those who had received HAART for at least 4 months, had experienced virologic failure (HIV-RNA >1000 copies/mL), had a genotypic resistance test performed at failure, and had started a new HAART regimen with a follow-up of at least 6 months and at least 2 virologic controls within this period of time. This analysis is therefore based on new HAART regimens started after a genotypic test. All treatment regimens responding to these criteria and started between January 2000 and November 2005 were included.
Virologic Assays
Plasma HIV-RNA was assayed quantitatively (HIV-RNA 3.0 bDNA; Chiron, Emeryville, Calif) with a lower limit of quantification of 50 copies/mL.
Genotyping was performed by means of reverse transcriptase polymerase chain reaction (PCR) of the reverse transcriptase and protease gene. PCR products were sequenced using the ViroSeq-HIV-1 genotyping system and analyzed with genotyping system software version 2.5 (Applied Biosystems, Foster City, Calif).
The accuracy of all sequences was verified manually. None of the interpretation systems analyzed in this study were used for treatment decisions in this group of patients.
Interpretation Systems and Genotypic Susceptibility Scores
Genotypic mutation patterns from each patient were reinterpreted by the use of 3 different expert systems that consisted of rule-based algorithms. We used an expert system developed at our Institution (Bergamo), the Stanford HIVdb of Stanford University, and the expert system of the Rega Institute. 10, 11 The most recent versions available at the moment of analysis (May 2006) were used.
To calculate genotypic sensitivity scores (GSSs), the interpretations provided by the different systems were translated into numeric values. Each drug included into the postgenotype HAART regimen was assigned a susceptibility score ranging from 0 to 1 according to the predefined criteria listed in Table 1 .
The sum of the scores for individual drugs included in the postgenotypic HAART regimen provided the GSS of that regimen. Ritonavir, used at doses ≤200 mg every ≥12 hours (booster dose) was not considered to be an active drug.
Several virologic outcomes were used to evaluate the ability of the expert systems to predict the activity of HAART. We considered the reduction of viral load over the 6-month period following the postgenotypic therapy, but we also analyzed the virologic response using some predetermined HIV-RNA cutoffs: reduction of at least 0.5 log or 1 log or reduction below the assay limit (50 copies/mL).
Statistical Analysis
HIV-RNA values were log transformed before analysis. The descriptive results are presented as means ± standard deviation, medians with interquartile range, and percentages with 95% confidence intervals (CIs). Inferential statistics were performed using nonparametric tests: Wilcoxon, Kruskal-Wallis, and Mann-Whitney U tests. χ 2 or Fisher exact test was used to analyze categorical variables. Pairs of groups were compared only if a multiple test gave a significant result. All tests were 2 sided, and a P value less than .05 was taken as significant.
We employed receiver-operating characteristic (ROC) curves to evaluate the predictive capacity of the expert systems. 12 The ROC curves simultaneously look at the sensitivity and specificity of prediction when using a range of thresholds. A perfect discriminator would produce a curve that touches the top left-hand corner of the graph, and the area under the curve (AUC) would be 1.00. A discriminator no better than chance alone would produce a diagonal running from the bottom left to the top right corner of the graph and would have an AUC of 0.50. A 95% CI for the AUC not embracing the 0.50 value would indicate that the predictive system is performing significantly better than chance. The ROC curves are presented both graphically and as their AUC values (±95% CI).
All analyses were performed using the SPSS Statistical Software Package for Windows, version 13.0.
Results
Patients' Baseline Characteristics and HAART Regimens
A total of 533 patients were enrolled. Their mean age was 38.6 years (SD ±8.1), and 25.5% were female. HIV transmission categories were mostly represented by injection drug users (48.8%), followed by heterosexual (40.3%) and male homosexual (10.1%); other causes counted for the remaining 0.9%. A previous diagnosis of AIDS (Centers for Disease Control and Prevention class C criteria) was present in 29.3% of patients. A clade B HIV was present in 90% of samples; 7.0% harbored a recombinant form (CRF), 1.1% a clade C, and the remaining 1.2% other clades. The mean HIV-RNA level was 4.14 log copies/mL (SD ± 0.7). During the considered period of time, these patients started 1132 postgenotypic HAART regimens, responding to the study selection criteria. As the predictive ability of the systems did not significantly differ when the analysis was performed on all available genotypes or restricted to the first genotype of each patient (533 tests, see below), all evaluations were carried forward considering all available genotypic tests.
The most commonly used nucleoside analogue (nucleoside reverse transcriptase inhibitor [NRTI]) was didanosine (44.3%) followed by stavudine (35.7%), lamivudine (22.3%), abacavir (20.1%), zidovudine (19.8%), and finally tenofovir (14.6%). As far as nonnucleoside reverse transcriptase inhibitors (NNRTIs) are concerned, 15.5% of regimens contained efavirenz and 11.6% nevirapine. A protease inhibitor (PI) was the third drug in 486 regimens, and in 67.7% (329) of the regimens, a boosted PI was used. Tipranavir was included in 1.1% of regimens, saquinavir in 2.3%, indinavir in 3.4%, atazanavir in 3.6%, amprenavir in 5.7%, nelfinavir in 8.9%, and lopinavir in 17.9%.
Genotyping Results
The genotype analysis showed a mean number of 8. For descriptive purposes, as an example, the detected panel of mutations in the 1132 performed genotypes as interpreted with the Bergamo expert system is reported in Figure 1 .
The prediction of high resistance was unevenly distributed, with 3TC and emtricitabine (FTC) showing the worst prediction (almost 50%), while other NRTIs were always below the 35% threshold; TDF was the best performer with a 6% prediction of high resistance. An elevated rate of high resistance was also predicted for NNRTI (between 45% and 60%), while the prediction was better for PIs, especially the most recently marketed, with TPV showing only a 3.4% prediction of high resistance.
Prediction of Virologic Outcomes
The ROC curve analysis for the probability to correctly predict the considered virologic outcome was similar when it was restricted to the first genotype executed in each patient (533 tests) or when it considered all available tests. As an example, in the first case, the probability to correctly predict the possibility to obtain a reduction of HIV-RNA of at least 1 log obtained an AUC value of 0.728 (95% CI, 0.684-0.772) according to the Bergamo system, of 0.726 (95% CI, 0.682-0.770) according to the Stanford system, and of 0.723 (95% CI, 0.679-0.767) with the Rega system. The same parameters obtained on the whole sets of genotypes is reported in Figure 2 .
The GSSs calculated by the 3 expert systems were congruent (difference ≤0.5 units) in 86.2% of cases. In 13.7% of cases, only 1 of the systems calculated a difference of ≥1 unit, while in only 1 case (0.1%) did each system yield a different result. When analyzed by means of ROC curves (Table 2) , the similar performance of each expert system is shown by the extremely high value of the AUC, invariably approaching the unit.
The GSS value was strongly associated (P < .0001) with the virologic outcome of the postgenotypic HAART. GSS, calculated with any of the studied algorithms, predicted, in a statistically significant (P < .0001) and similar way, the entity of the reduction of plasma HIV-RNA after 6 months of therapy ( Figure 3) . Independently of the expert system used for determining the GSS, a value of at least 1 was necessary to observe an initial virologic result, but a GSS value of at least 2 was necessary to observe a clinically relevant reduction of HIV-RNA. A similar statistical significance (P < .0001) correlated the GSS calculated with any of the systems with any of the other virologic end points: the proportion of patients with a reduction of HIV-RNA of at least 0.5 log, of at least 1 log, or below the detection limit of the assay (50 copies/mL).
The ROC curve analysis for the probability to correctly predict the possibility to obtain a reduction of HIV-RNA of at least 1 log is reported in Figure 2 . In any case, the expert systems showed a highly significant prediction efficiency. The Bergamo expert system, as an example, showed an AUC value of 0.753 with a 95% CI ranging from 0.725 to 0.781. The 95% CI was far from the AUC value of 0.50, demonstrating that the expert system prediction to obtain the desired outcome was significantly different (in this case, P < .0001) from simple chance. The AUCs obtained by the 2 other expert systems were superimposable (Figure 2) . Similar results were obtained when different virologic outcomes were considered. When a less demanding HIV-RNA reduction ≥0.5 log was used, the Bergamo system presented an AUC value of 0.741 (95% CI, 0.712-0.770), the Stanford system of 0.742 (95% CI, 0.712-0.771), and the Rega system of 0.731 (95% CI, 0.701-0.761). Similarly, for a more stringent outcome (HIV-RNA <50 copies/mL), the results were 0.696 (95% CI, 0.665-0.727), 0.699 (95% CI, 0.668-0.730), and 0.696 (95% CI, 0.664-0.727), respectively. In all cases, the prediction ability was highly statistically significant (P < .0001). The predictive capacity of the algorithms was not influenced by the type of antiviral drugs used. As an example, considering the Bergamo expert system and its ability to predict the possibility to obtain a reduction of HIV-RNA of at least 1 log, when NNRTIbased HAART regimens were used, the ROC curve AUC was 0.771 (95% CI, 0.717-0.825), while the same value, in the case of a PI-based therapy, was 0.723 (95% CI, 0.668-0.777).
The ROC curve analysis was used to compare the interpretation provided by each algorithm and the consequent prediction of HAART activity. To perform this analysis, the prediction of an expert system was used as a standard and that of an alternative one was tested against it. As shown in Table 2 , the ROC curve AUC for each comparison was very close to the unit (range, 0.910-0.982), meaning that the strength of the correlation for the considered algorithm was very high (P < .0001).
Discussion
The most widely used method to detect HIV drug resistance is the genotypic analysis performed by standardized automated sequencing of the DNA of the pol region. The complex mutational patterns in this region associated with drug resistance have led to the development of different expert systems to help clinicians in the interpretation of the mutational pattern J INT ASSOC PHYSICIANS AIDS CARE 6(2); 2007 91 Virologic Outcome of Salvage Antiretroviral Treatment Figure 3 . HIV-RNA log reduction at the sixth month of the postgenotypic highly active antiretroviral therapy according to the genotypic sensitivity score calculated by the 3 expert systems (median, interquartile range, and outliers). and the consequent sensitivity of specific antiretroviral drugs. The usefulness of these rule-based systems lies in their ability to predict how a given HAART regimen would act in the presence of a defined mutational landscape. For the clinician, the gold standard in evaluating the efficiency of these predictive systems is the reduction and control of HIV replication once the salvage regimen is used. 13 To obtain this information, in the present study, we had to set some predefined rules. First, as each of the considered algorithms reports its results differently, we had to normalize the information offered by each system. We chose to convert the information to a numeric score ranging from 0 to 1 to calculate a GSS score. As some of the interpretation systems do not suggest a numeric drug susceptibility value, any choice would have appeared somehow arbitrary. To limit this possibility and to make our results comparable with previously published data, we adopted values already used in the literature 4, 8, 10 and suggested by the authors of the systems. 11 The same is true for how the descriptive definitions of sensitivity were linked to a specific numeric value. 11 A second arbitrary choice was related to the timing of virologic response. As our casuistry included patients with different treatment experiences, we chose a rather conservative period of time (6 months) to evaluate virologic response. In our opinion, this allowed us to reduce wrong interpretations of the results. A shorter period of time would have, on one hand, carried forward the risk of judging as active treatments having just a transient, short-lasting antiviral effect (eg, highly experienced patients assuming a single active drug). On the other hand, a shorter period of time could make us judge, as ineffective, treatments requiring a longer follow-up to exert their full activity (eg, patients starting HAART with a very high viral load). Furthermore, a 6-month follow-up period was previously used to perform a similar analysis, 4,10 and, in our case, this requirement led to the exclusion of a very small number of patients (23 subjects).
By setting these limits, the performance of all 3 analyzed systems was highly significant. All precisely predicted the 6-month virologic outcome. When the 6-month variation of HIV-RNA blood levels was considered, the 3 expert systems were able to differentiate even the presence of a partially active drug (score 0.5) into the regimen. Using this evaluation end point, an initial effect was observed when at least 1 active drug was introduced into the regimen; however, a clinically relevant effect was observed only when at least 2 active drugs were used. These results are in agreement with recently reported therapeutic data in highly experienced patients. 14, 15 The expert systems' ability to predict the outcome was demonstrated when predetermined and standardized cutoffs (0.5 or 1 log reduction or reduction below 50 copies/mL) were used, too. In this case, the ROC curve analysis invariably calculated AUC values significantly different from 0.50 or, in other words, from a prediction merely due to pure chance. 12 The interpretation efficiency of the systems was not influenced by the type of drugs used in rescue therapy. The ROC curve AUC for NNRTI-based HAART regimens (Bergamo system) was just slightly greater than that obtained for boosted-PI-based therapies. This result probably reflects the simple mechanism of genotypic resistance to NNRTIs, which is often based on the presence of single-point mutations, but also highlights the ability of the systems to deal with more complex and articulated mutational patterns such as those observed in the case of PIs, in which the net residual activity is the result of multiple additive and subtractive interactions among mutations. 7 Drug resistance is not the only reason for virologic failure of HAART regimens. Another major determinant is lack of adherence. 16, 17 A possible limitation of this study is that we could not adjust our analysis for adherence levels. However, as adherence could not be anything more than optimal (100%), our results eventually underestimate the predictive capacity of the expert systems. In fact, it has been reported that nonadherence markedly reduced the association between baseline susceptibility interpretations and virologic outcome of salvage therapy. 4 Another possible limitation of this study lies in the retrospective nature of the analysis. We tried to limit possible analytical biases by excluding patients for whom any expert interpretation system was used for treatment decisions.
On the other hand, a point of strength of this study is the size of the sample, as, to our knowledge, genotypic expert systems have never been validated before on more than 1000 specific treatments including a large proportion of boosted-PI-based regimens. [4] [5] [6] 8, 18 The large sample size may partially explain the high interpretation concordance among the expert systems we observed in contrast with previously reported results. [4] [5] [6] In fact, eventual discrepancies on single genotypes could have been diluted by the high number of concordant predictions. Another possible explanation for this result is that nowadays, our understanding of genotypic HIV drug resistance has improved, and recent rule-based algorithms reflect our better knowledge of mutations' effects on drug activity.
In conclusion, we have demonstrated that rule-based algorithms for the interpretation of HIV genotypic resistance yield congruent results and may effectively predict the virologic outcome of rescue therapy. Their use may help clinicians in interpreting complicated mutational patterns and in making therapeutic choices.
